A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC).
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2013
At a glance
- Drugs AT 101 (Primary)
- Indications Adrenal cancer
- Focus Therapeutic Use
- 07 Feb 2013 New source identified and integrated (Mayo Clinic; 08-001344).
- 06 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 06 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.